VEA
MRSN

Virtus ETF Advisers’s Mersana Therapeutics MRSN Stock Holding History

Virtus ETF Advisers’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-414
Closed -$13.2K – 453
2023
Q3 		$13.2K Sell
414
-41
-9% -$1.95K 0.01% 432
2023
Q2 		$37.5K Sell
455
-112
-20% -$16.4K 0.02% 433
2023
Q1 		$58.2K Sell
567
-218
-28% -$30.6K 0.03% 424
2022
Q4 		$115K Sell
785
-617
-44% -$104K 0.06% 429
2022
Q3 		$237K Buy
1,402
+10
+0.7% +$1.63K 0.09% 297
2022
Q2 		$161K Buy
1,392
+260
+23% +$24.5K 0.06% 314
2022
Q1 		$113K Sell
1,132
-67
-6% -$7.83K 0.05% 282
2021
Q4 		$186K Buy
1,199
+632
+111% +$123K 0.07% 236
2021
Q3 		$134K Sell
567
-29
-5% -$8.47K 0.06% 359
2021
Q2 		$203K Buy
596
+125
+27% +$47.3K 0.08% 335
2021
Q1 		$190K Buy
471
+9
+2% +$4.37K 0.08% 332
2020
Q4 		$308K Sell
462
-157
-25% -$87.3K 0.13% 201
2020
Q3 		$288K Sell
619
-84
-12% -$42.4K 0.15% 232
2020
Q2 		$411K Buy
+703
New +$240K 0.19% 188

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Virtus ETF Advisers's MRSN Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 414 shares — an estimated $13.2K sold.

Virtus ETF Advisers first reported a position in MRSN in Q2 2020 and held it in 14 quarters. The position peaked at $411K in Q2 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Virtus ETF Advisers reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 414 Mersana Therapeutics shares in Q4 2023, an estimated $13.2K.
  • Virtus ETF Advisers first reported a position in Mersana Therapeutics in Q2 2020 and held it in 14 quarters.
  • Virtus ETF Advisers's Mersana Therapeutics position peaked at $411K in Q2 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.